Imagine a test that could tell you if you were infected with COVID-19 before you had a single symptom, came at an affordable price without the need to go to a doctor, and returned results in minutes.
Those who tested positive could swiftly quarantine themselves, while those who tested negative could head to work or spend time with family without fear of spreading infection.
That’s the vision behind a new University of Colorado-born technology that researchers are fast-tracking in hopes of not only helping to curb the current pandemic but also radically change the way we track disease in the future.
“With most infectious diseases, by the time you develop symptoms you have already been contagious for days and out and about spreading it to people,” said Nicholas Meyerson, a scientist in the department of Molecular, Cellular and Developmental Biology (MCDB) at CU Boulder and CEO of Darwin Biosciences, a startup formed to commercialize the SickStick. “Our device acts at the earliest stage of infection. It knows you’re sick before you do.”
For a decade, Meyerson has been working with MCDB Professor Sara Sawyer, a virologist at the BioFrontiers Institute, to understand the basic science underlying the body’s early immune response to infection.
While most labs and tests have focused on antibodies – proteins in the blood that signal a mounting defense against a bacteria or virus – Sawyer’s lab has taken a different approach.
“Antibodies don’t arise in your body until after the copy number of a pathogen has gotten very large,” said Sawyer, noting that this can take days or – in the case of coronavirus – more than two weeks. “They are the last chapter in the immunology textbook.
We specialize in the first chapter – the smoke signals that infected cells send off to indicate a pathogen is present.”
Disease ‘smoke signals’
Those smoke signals, called nucleic acids, rise up in the cells within hours of exposure to a virus and can make their way into saliva.
With this in mind, and a $3 million grant from the Department of Defense in hand, Sawyer and Meyerson set out two years ago to develop a new kind of diagnostic test.
Also involved are researchers from the labs of Associate Professor of MCDB Robin Dowell, Biochemistry Professor Roy Parker and Dr. Eric Poeschla at the CU Anschutz Medical Campus.
“There is a lot of utility in knowing that people are getting sick before they go and infect others, yet there is currently only one tool for knowing that – the thermometer,” said Sawyer, noting that because some pathogens don’t prompt fever it’s an unreliable tool. “Our technology fills a void.”
The user spits in a receptacle, sticks in a strip that soaks up the contents and within minutes – much like with an at-home pregnancy test – a series of lines appear.
The original prototype was designed to be agnostic about the kind of infection present: one line for healthy; two lines for sickness brewing.
The researchers envisioned it being used on military bases. In another scenario, seemingly healthy civilians who had been exposed to a virus could pluck a SickStick off the shelf at the local drugstore and test themselves.
Then, coronavirus happened, and Meyerson and Sawyer quickly pivoted.
They’ve been in the lab ever since, working to identify biomarkers that will enable them to add a third line to the test that would indicate whether the user has coronavirus.
“Even before coronavirus it wasn’t hard to convince people that this device could be useful,” said Meyerson, noting that while antibody tests help identify who is sick or recovered, they do little to prevent unknowing carriers from spreading disease.
“Now, in this world we are living in, where people are social distancing and self-quarantining, it’s very clear that it’s the device we need.”
From lab to market
Under normal circumstances, the path from lab to commercial availability could be years. But these circumstances are anything but normal.
“We have a very ambitious goal of six months,” said Sawyer.
With patents already secured, they have several clinical trials in the works to confirm that the test is accurate in predicting respiratory infections in general, and help them refine biomarkers to predict COVID-19 specifically.
This week, Darwin Biosciences won first place at the New Venture Challenge event, earning it an additional $55,000 boost on top of a $126,000 grant from Venture Partners, a CU Boulder office that also provides mentoring and support to researcher-led startups.
In March, the company welcomed a new COO, Rick Whitcomb, a long-time biotech entrepreneur from Lyons whom they met at a Venture Partners event.
“I would be remiss not to call out the amazing biotech support network that CU Boulder and this community has offered us,” said Sawyer. “We are just university scientists who discovered we had our hands on something that can really matter. It’s remarkable how far we’ve come so fast.”
The SickStick team is now working on an advanced prototype and exploring what it will take to get clearance from the Food and Drug Administration, which has sharply expedited its review process for diagnostic tests for COVID-19.
While their timeline may not help to address the current situation, if the second wave of COVID-19 hits next fall, they’re confident SickStick could help prevent it from taking hold. And when other epidemics emerge, we’ll be ready.
“Long-term,” said Meyerson, “this could transform how we think about diagnosing disease.”
Current point of view
The present outbreak of the 2019 coronavirus strain (COVID-19) constitutes a public health emergency of global concern .
International centers for disease control and prevention are monitoring this infectious disease outbreak; symptoms of COVID-19 infection include fever, cough, and acute respiratory disease, with severe cases leading to pneumonia, kidney failure, and even death. The severe respiratory illness caused by the COVID-19 was first detected in Wuhan, Hubei, China, and infections have spread worldwide .
Currently, the available COVID-19 genome sequences from clinical samples suggest that this viral emergence is related to bat coronaviruses . Although the coronavirus infection in humans frequently presents with mild severity, the betacoronavirus infection of either the severe acute respiratory syndrome coronavirus (SARS-CoV)  or the Middle East respiratory syndrome coronavirus (MERS-CoV)  resulted in higher mortality rates .
Given the novelty of COVID-19, some characteristics of the virus remain yet unknown. The COVID-19 outbreak serves as both a reminder and an opportunity to assist. Considering that COVID-19 was recently identified in saliva of infected patients , the COVID-19 outbreak is a reminder that dental/oral and other health professionals must always be diligent in protecting against the spread of infectious disease, and it provides a chance to determine if a non-invasive saliva diagnostic for COVID-19 could assist in detecting such viruses and reducing the spread.
Diagnosis of COVID-19 can theoretically be performed using salivary diagnosis platforms. Some virus strains have been detected in saliva as long as 29 days after infection [18, 19], indicating that a non-invasive platform to rapidly differentiate the biomarkers using saliva could enhance disease detection.  Saliva samples could be collected in patients who present with oropharyngeal secretions as a symptom [12, 13].
Bearing in mind the requirement of a close contact between healthcare workers and infected patients to collect nasopharyngeal or oropharyngeal samples, the possibility of a saliva self-collection can strongly reduce the risk of COVID-19 transmission. Besides, the nasopharyngeal and oropharyngeal collection promotes discomfort and may promote bleeding especially in infected patients with thrombocytopenia.
The sputum of a lower respiratory tract was produced by only 28% of COVID-19 patients, which indicates a strong limitation as specimen to diagnostic evaluation . We suggest that there is a minimum of three different pathways for COVID-19 to present in saliva: firstly, from COVID-19 in the lower and upper respiratory tract [2, 3] that enters the oral cavity together with the liquid droplets frequently exchanged by these organs.
Secondly, COVID-19 present in the blood can access the mouth via crevicular fluid, an oral cavity-specific exudate that contains local proteins derived from extracellular matrix and serum-derived proteins .
Finally, another way for COVID-19 to occur in the oral cavity is by major- and minor-salivary gland infection, with subsequent release of particles in saliva via salivary ducts. It is essential to point out that salivary gland epithelial cells can be infected by SARS-CoV a short time after infection in rhesus macaques, suggesting that salivary gland cells could be a pivotal source of this virus in saliva .
Additionally, the production of SARS-CoV-specific secretory immunoglobulin A (sIgA) in the saliva of animal models intranasally immunized was previously shown . Considering the similarity of both strains, we speculate that salivary diagnosis of COVID-19 could also be performed using specific antibodies to this virus.
Further studies are needed to investigate the potential diagnostic of COVID-19 in saliva and its impact on transmission of this virus, which is crucial to improve effective strategies for prevention, especially for dentists and healthcare professionals that perform aerosol-generating procedures. Saliva can have a pivotal role in the human-to-human transmission, and salivary diagnostics may provide a convenient and cost-effective point-of-care platform for COVID-19 infection.
- The Lancet (2020) Emerging understandings of COVID-19. Lancet. 395(10221):311. https://doi.org/10.1016/S0140-6736(20)30186-0
- Zhu N, Zhang D, Wang W et al (2019) China Novel Coronavirus Investigating and Research Team. A novel coronavirus from patients with pneumonia in China. N Engl J Med:2020. https://doi.org/10.1056/NEJMoa2001017
- Zhou P, Yang XL, Wang XG et al (2020) A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. https://doi.org/10.1038/s41586-020-2012-7
- Ksiazek TG, Erdman D, Goldsmith CS et al (2003) A novel coronavirus associated with severe acute respiratory syndrome. N Engl J Med 348(20):1953–1966
- de Groot RJ, Baker SC, Baric RS, Brown CS, Drosten C, Enjuanes L, Fouchier RA, Galiano M, Gorbalenya AE, Memish ZA, Perlman S, Poon LL, Snijder EJ, Stephens GM, Woo PC, Zaki AM, Zambon M, Ziebuhr J (2013) Middle East respiratory syndrome coronavirus (MERS-CoV): announcement of the Coronavirus Study Group. J Virol 87(14):7790–7792. https://doi.org/10.1128/JVI.01244-13
- Hui DSC, Zumla A (2019) Severe acute respiratory syndrome: historical, epidemiologic, and clinical features. Infect Dis Clin N Am 33(4):869–889. https://doi.org/10.1016/j.idc.2019.07.001
- To KK, Tsang OT, Chik-Yan Yip C et al (2020) Consistent detection of 2019 novel coronavirus in saliva. Clin Infect Dis. https://doi.org/10.1093/cid/ciaa149
- Huang C, Wang Y, Li X et al (2020) Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet S0140-6736(20):30183–30185. https://doi.org/10.1016/S0140-6736(20)
- World Health Organization – WHO (2020a) Emergencies preparedness, response. Pneumonia of unknown origin – China disease outbreak news; 12 January, Accessed 12 Jan 2020. Available at: https://www.who.int/csr/don/12-january-2020-novel-coronavirus-china/en/
- Wu A, Peng Y, Huang B et al (2020) Genome composition and divergence of the novel coronavirus (COVID-19) originating in China. Cell Host Microbe S1931–3128(20):30072-X. https://doi.org/10.1016/j.chom.2020.02.001
- Shu Y, McCauley J (2017) GISAID: global initiative on sharing all influenza data – from vision to reality. Euro Surveill 22(13). https://doi.org/10.2807/1560-7917.ES.2017.22.13.30494
- ECDC – European Centre for Disease Prevention and Control; European surveillance for human infection with novel coronavirus (COVID-19); 22 January, Accessed 28 Jan 2020. Available at: https://www.ecdc.europa.eu/en/european-surveillance-human-infection-novel-coronavirus-COVID-19
- World Health Organization-WHO (2020) Global surveillance for human infection with novel coronavirus (COVID-19) Interim guidance. 21 January, Accessed 28 Jan 2020. Available at: https://www.who.int/docs/default-source/coronaviruse/20200121-global-surveillance-for-COVID-19.pdf
- Xie X, Li Y, Sun H, Liu L (2009) Exhaled droplets due to talking and coughing. J R Soc Interface 6(Suppl 6):S703–S714. https://doi.org/10.1098/rsif.2009.0388.focus15.Chan JF, Yuan S, Kok KH et al (2020) A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster. Lancet. https://doi.org/10.1016/S0140-6736(20)30154-9
- Wang D, Hu B, Hu C et al (2020) Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA. https://doi.org/10.1001/jama.2020.1585
- Group of Interventional Respiratory Medicine, Chinese Thoracic Society (2020) [Expert consensus for bronchoscopy during the epidemic of 2019 Novel Coronavirus infection (Trial version)]. 43(0):E006. doi: https://doi.org/10.3760/cma.j.issn.1001-0939.2020.0006
- Barzon L, Pacenti M, Berto A, Sinigaglia A, Franchin E, Lavezzo E, Brugnaro P, Palù G (2016) Isolation of infectious Zika virus from saliva and prolonged viral RNA shedding in a traveller returning from the Dominican Republic to Italy, January 2016. Euro Surveill 21(10):30159. https://doi.org/10.2807/1560-7917.ES.2016.21.10.30159
- Zuanazzi D, Arts EJ, Jorge PK, Mulyar Y, Gibson R, Xiao Y, Bringel Dos Santos M, Machado MAAM, Siqueira WL (2017) Postnatal identification of zika virus peptides from saliva. J Dent Res 96(10):1078–1084. https://doi.org/10.1177/0022034517723325
- Segal A, Wong DT (2008) Salivary diagnostics: enhancing disease detection and making medicine better. Eur J Dent Educ 12(Suppl 1):22–29. https://doi.org/10.1111/j.1600-0579.2007.00477.x
- Silva-Boghossian CM, Colombo AP, Tanaka M et al (2013) Quantitative proteomic analysis of gingival crevicular fluid in different periodontal conditions. PLoS One 8(10):e75898. https://doi.org/10.1371/journal.pone.0075898
- Liu L, Wei Q, Alvarez X et al (2011) Epithelial cells lining salivary gland ducts are early target cells of severe acute respiratory syndrome coronavirus infection in the upper respiratory tracts of rhesus macaques. J Virol 85(8):4025–4030. https://doi.org/10.1128/JVI.02292-10
- Lu B, Huang Y, Huang L, Li B, Zheng Z, Chen Z, Chen J, Hu Q, Wang H (2010) Effect of mucosal and systemic immunization with virus-like particles of severe acute respiratory syndrome coronavirus in mice. Immunology. 130(2):254–261. https://doi.org/10.1111/j.1365-2567.2010.03231.x